secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001193125-25-230984
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Phathom Pharmaceuticals appoints Sanjeev Narula as CFO and Business Officer effective Oct 6, 2025
--------------------------------------------------------------------------------

- Sanjeev Narula named Chief Financial and Business Officer; replaces Robert Breedlove as principal financial officer.
- Initial base salary of $550,000 with annual target bonus of 50% of base salary.
- Receives stock options for 200,000 shares (4-year vest) and 144,000 RSUs (3-year annual vest).
- Narula previously CFO of Intra-Cellular Therapies and Viatris; brings extensive biopharma finance experience.
- Robert Breedlove continues as Vice President, Finance and principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/0001193125-25-230984-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312525230984/d76139d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-230984

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer